TScan Therapeutics (TCRX) to Release Earnings on Tuesday

TScan Therapeutics (NASDAQ:TCRX) will likely be releasing its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect the company to post earnings of ($0.29) per share and revenue of $1.8750 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 9:30 AM ET.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.22). TScan Therapeutics had a negative net margin of 1,360.61% and a negative return on equity of 91.94%. The business had revenue of $0.98 million for the quarter, compared to analyst estimates of $2.50 million. On average, analysts expect TScan Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TScan Therapeutics Price Performance

TCRX traded up $0.01 during trading on Tuesday, hitting $0.73. 477,452 shares of the stock traded hands, compared to its average volume of 718,603. The business has a 50 day moving average price of $0.95 and a 200 day moving average price of $1.04. The company has a debt-to-equity ratio of 0.34, a current ratio of 6.65 and a quick ratio of 6.65. TScan Therapeutics has a twelve month low of $0.72 and a twelve month high of $2.57. The company has a market cap of $47.84 million, a price-to-earnings ratio of -0.76 and a beta of 1.06.

Analyst Ratings Changes

TCRX has been the topic of several recent analyst reports. Wedbush reiterated an “outperform” rating and issued a $5.00 price target on shares of TScan Therapeutics in a research note on Tuesday, June 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of TScan Therapeutics in a research note on Friday, July 17th. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 target price on shares of TScan Therapeutics in a research report on Tuesday, June 23rd. Finally, Wall Street Zen downgraded TScan Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, TScan Therapeutics has an average rating of “Hold” and an average target price of $6.00.

Institutional Trading of TScan Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Panagora Asset Management Inc. bought a new position in shares of TScan Therapeutics in the 4th quarter valued at $25,000. HRT Financial LP bought a new stake in TScan Therapeutics during the 4th quarter worth $26,000. Boothbay Fund Management LLC grew its position in TScan Therapeutics by 50.0% during the 2nd quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock worth $35,000 after acquiring an additional 8,121 shares during the last quarter. Marshall Wace LLP acquired a new position in TScan Therapeutics in the 2nd quarter worth about $78,000. Finally, Voleon Capital Management LP acquired a new position in TScan Therapeutics in the 3rd quarter worth about $87,000. Institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.